

Bamlanivimab no longer recommended due to COVID variants in Colorado

The monoclonal antibody bamlanivimab is no longer recommended as monotherapy for the treatment of COVID-19 in Colorado.

The prevalence of B.1.427/B.1.429 variants is now estimated to be greater than 20% of all Colorado cases; mutations in these variants are expected to confer resistance to bamlanivimab.

https://drive.google.com/file/d/1AehPczjqZg-Zq 3nv- 2sKMK9Um1TiKj/view?usp=sharing

Doc Shepherd (drdavidshepherd.blogspot.com)

DS